Abstract
Research staging (Simuni et al., 2024). However, identifying pathology, predicting disability, and monitoring treatment response represent distinct clinical objectives. This research topic brings together genetic, molecular, imaging, and clinical investigations to examine how complementary measurements might support earlier detection and more informative characterization of PD. Its contributions also expose the distance between a promising relationship and a clinically useful biomarker.Genetic studies emphasize that biological interpretation depends on population context. Arias-Carrión et al. synthesize evidence from Mexican populations, highlighting established PD-related pathways alongside methodological heterogeneity and limited ancestry-aware analyses.Their findings reinforce the importance of the broader multi-ancestry research agenda (Kim et al., 2024). Soraya et al. combine preliminary Indonesian family observations with a meta-analysis of apolipoprotein E (APOE) ε4 and clinical features. The pooled evidence associates ε4 carriage with modestly earlier onset, without significant differences in Hoehn-Yahr stage or Mini-Mental State Examination scores. These endpoint-specific findings caution against treating a genetic association with onset as evidence of accelerated progression; the very small local sample also precludes population-level inference. The need to distinguish diagnostic discrimination from biological interpretation is particularly clear in the study by Li, Luo, and Bai. Plasma α-synuclein distinguished PD from healthy controls with an AUC of 0.976, but this estimate came from a relatively small cohort of 52 patients and 62 healthy controls. Performance against healthy individuals does not establish differential diagnostic value in patients with atypical or secondary parkinsonism. Moreover, nominal associations between quantitative susceptibility mapping (QSM) measures and clinical features did not survive age adjustment and correction for multiple comparisons, illustrating the importance of confounding control. Peripheral α-synuclein concentrations were not directly associated with regional susceptibility. These results leave the complementary value of the two measurements unresolved.Total plasma α-synuclein should also be distinguished from seed amplification measures of pathological aggregation. Replication with standardized sample handling and clinically relevant disease controls is needed before diagnostic performance can be generalized. and meta-analysis of brain-derived neurotrophic factor (BDNF). Blood BDNF was lower in PD overall, but the difference was significant in serum, not plasma, and heterogeneity was substantial.Only three CSF studies were available, with no significant pooled difference and unstable results.Lower serum BDNF was also associated with cognitive impairment, supporting further phenotype-specific investigation. However, platelet release during sample processing and incompletely assessed medication effects complicate interpretation. These findings caution against treating peripheral BDNF as a direct measure of central neurotrophic activity or an established progression marker.Accessible peripheral measurements offer another route to detailed phenotyping. Dong et al. Even if an intervention changes both microbial profiles and symptoms, mediation analyses and temporal evidence will be needed to determine whether microbial changes contribute to improvement.Across these contributions, the key translational question is which clinical decisions a biomarker could help inform. Future studies should prespecify whether the intended use is prodromal identification, differential diagnosis, prognosis, or response monitoring. Longitudinal cohorts need repeated measurements and outcomes meaningful to patients, including cognitive decline, falls, and loss of independence. Models should be evaluated in independent settings, across ancestry groups and disease stages, with attention to calibration, confounding, and added value over clinical assessment. Multimodal integration is justified when it improves those decisions sufficiently to offset additional cost and burden. The contribution of this Research Topic is to identify promising biological and clinical connections while clarifying the validation needed to make them useful in PD research and care.